Day One Bio Files S-8 POS for Employee Stock Plans
Ticker: DAWN · Form: S · Filed: Apr 23, 2026 · CIK: 0001845337
Sentiment: neutral
Topics: employee-benefits, securities-registration
TL;DR
Day One Bio just filed to register more stock for its employees. Keep an eye on dilution.
AI Summary
Day One Biopharmaceuticals, Inc. filed an S-8 POS form on April 23, 2026, registering an unspecified number of securities for issuance under its employee benefit plans. This filing is a post-effective amendment, indicating adjustments or updates to previously registered securities for employee compensation. The company's business address is 1800 Sierra Point Parkway, Suite 200, Brisbane, CA 94005.
Why It Matters
This filing relates to the company's equity compensation strategy, which can impact employee incentives and future share dilution.
Risk Assessment
Risk Level: low — An S-8 filing is a routine registration of securities for employee benefit plans and does not typically represent a significant new risk event.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Filer
- 0001845337 (company) — CIK Number
- 2026-04-23 (date) — Filing Date
- 1800 Sierra Point Parkway, Suite 200 Brisbane CA 94005 (address) — Mailing and Business Address
FAQ
What type of securities are being registered?
The filing is an S-8 POS, which registers securities to be offered to employees in employee benefit plans.
When was this filing accepted by the SEC?
The filing was accepted on April 23, 2026, at 09:00:56.
What is the CIK number for Day One Biopharmaceuticals, Inc.?
The CIK number for Day One Biopharmaceuticals, Inc. is 0001845337.
What is the company's stated business address?
The business address is 1800 Sierra Point Parkway, Suite 200, Brisbane, CA 94005.
What does 'S-8 POS' signify?
S-8 POS indicates a registration statement for securities to be offered under an employee benefit plan, and 'POS' signifies a post-effective amendment.
Filing Details
This Form S (Form S) was filed with the SEC on April 23, 2026 regarding 8 POS - Day One Biopharmaceuticals, Inc. (DAWN).